7,732 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Boussard & Gavaudan Investment Management LLP

Boussard & Gavaudan Investment Management LLP acquired a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 7,732 shares of the medical instruments supplier's stock, valued at approximately $2,036,000.

Other institutional investors also recently added to or reduced their stakes in the company. Baillie Gifford & Co. increased its position in shares of Insulet by 3.5% during the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock worth $614,998,000 after purchasing an additional 79,982 shares in the last quarter. Geode Capital Management LLC increased its position in Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock valued at $403,339,000 after buying an additional 22,850 shares in the last quarter. Norges Bank acquired a new stake in Insulet in the fourth quarter worth about $248,806,000. Artisan Partners Limited Partnership grew its stake in shares of Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after acquiring an additional 149,524 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Insulet by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier's stock valued at $168,902,000 after acquiring an additional 10,694 shares in the last quarter.

Insider Transactions at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

PODD has been the topic of several research analyst reports. Stifel Nicolaus boosted their target price on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Royal Bank of Canada began coverage on Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price on the stock. Citigroup lifted their price target on Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Canaccord Genuity Group increased their price objective on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, StockNews.com downgraded Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $292.06.

Insulet Price Performance

Shares of NASDAQ:PODD traded up $0.56 during midday trading on Tuesday, reaching $263.17. 142,848 shares of the company's stock traded hands, compared to its average volume of 704,961. The company has a fifty day simple moving average of $271.42 and a two-hundred day simple moving average of $259.20. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a market cap of $18.48 billion, a P/E ratio of 45.59, a PEG ratio of 3.62 and a beta of 1.29. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Equities analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.